Document Detail


Model analysis of tulobuterol patch formulations to explain the influence of drug release rate and transdermal transfer rate on the plasma concentration profile.
MedLine Citation:
PMID:  21963976     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
The purpose of this study was to compare the transdermal transfer profiles of brand and generic tulobuterol patch formulations and to evaluate possible changes of in vivo kinetics resulting from increased transdermal transfer by means of pharmacokinetic analysis using reported in vitro drug release rate data and plasma drug concentration profiles. On the assumption that the transdermal transfer rate constant (k2) would be constant (independent of formulation), the drug release rate constant from patch formulation (k1) was predicted to be almost equal to the k2 value (k1≈k2) in the brand formulation, but 2- to 4-fold higher than the k2 value (k1>k2) in the two generic formulations. Under normal conditions, there would be no marked difference in the plasma concentration profiles among the formulations. However, under conditions where transdermal transfer is increased (that is, higher k2), the plasma tulobuterol concentration was predicted to increase more rapidly, with higher C(max), and then to decrease more rapidly in the elimination phase after applying the generic formulations compared with the brand formulation. These different behaviors would be seen because the transdermal transfer of the generic formulations would be affected by k2, whereas k1 is still rate-determining for the brand formulation. These results suggest that bronchial asthma patients with risk factors for impaired skin barrier function, including atopic dermatitis, long-term treatment with steroids, and advanced age, should be carefully monitored for reduced treatment efficacy or adverse drug reactions after application of rapid-release generic tulobuterol patch formulations.
Authors:
Tetsuo Watanabe; Hiroki Satoh; Satoko Hori; Akiko Miki; Hisakazu Ohtani; Yasufumi Sawada
Related Documents :
24397566 - An approach to heparin and lidocaine hypersensitivity for the interventional nephrologist.
24350906 - Synthesis and evaluation of a nanoglobular dendrimer 5-aminosalicylic acid conjugate wi...
18221196 - Galanthamine, a natural product for the treatment of alzheimer's disease.
24879716 - The role of novel anticoagulants in the management of venous thromboembolism.
11365426 - Options when hiv treatments fail.
22998536 - Baclofen for the treatment of alcohol dependence.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan     Volume:  131     ISSN:  1347-5231     ISO Abbreviation:  Yakugaku Zasshi     Publication Date:  2011  
Date Detail:
Created Date:  2011-10-03     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0413613     Medline TA:  Yakugaku Zasshi     Country:  Japan    
Other Details:
Languages:  eng     Pagination:  1483-92     Citation Subset:  IM    
Affiliation:
Hojin Pharmacy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Chemopreventive effects of 5-Fluorouracil and lactoferrin on goldfish intestinal carcinogenesis indu...
Next Document:  Molecular Cloning and Functional Characterization of a Novel Gene Encoding Human Prostaglandin Carri...